Switch theme
Sign up to access all valuation multiples
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
2020
570
LTM Revenue $240M
LTM EBITDA $21.1M
$309M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Maravai LifeSciences has a last 12-month revenue of $240M and a last 12-month EBITDA of $21.1M.
In the most recent fiscal year, Maravai LifeSciences achieved revenue of $259M and an EBITDA of -$157M.
Maravai LifeSciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Maravai LifeSciences valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $289M | $259M | XXX | XXX | XXX |
| Gross Profit | $714M | $140M | XXX | XXX | XXX |
| Gross Margin | 247% | 54% | XXX | XXX | XXX |
| EBITDA | $712M | -$157M | XXX | XXX | XXX |
| EBITDA Margin | 247% | -61% | XXX | XXX | XXX |
| Net Profit | $220M | -$119M | XXX | XXX | XXX |
| Net Margin | 76% | -46% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Maravai LifeSciences's stock price is $2.
Maravai LifeSciences has current market cap of $254M, and EV of $309M.
See Maravai LifeSciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $309M | $254M | XXX | XXX | XXX | XXX | $-0.14 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Maravai LifeSciences has market cap of $254M and EV of $309M.
Maravai LifeSciences's trades at 1.3x LTM EV/Revenue multiple, and 14.6x LTM EBITDA.
Analysts estimate Maravai LifeSciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Maravai LifeSciences and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $309M | XXX | XXX | XXX |
| EV/Revenue | 1.2x | XXX | XXX | XXX |
| EV/EBITDA | -2.0x | XXX | XXX | XXX |
| P/E | -1.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -13.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpMaravai LifeSciences's NTM/LTM revenue growth is -17%
Maravai LifeSciences's revenue per employee for the last fiscal year averaged $0.5M, while opex per employee averaged $0.3M for the same period.
Over next 12 months, Maravai LifeSciences's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Maravai LifeSciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Maravai LifeSciences and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -10% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -61% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -122% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -78% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.5M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 7% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 70% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Suven Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Maravai LifeSciences acquired XXX companies to date.
Last acquisition by Maravai LifeSciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Maravai LifeSciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Maravai LifeSciences founded? | Maravai LifeSciences was founded in 2020. |
| Where is Maravai LifeSciences headquartered? | Maravai LifeSciences is headquartered in United States of America. |
| How many employees does Maravai LifeSciences have? | As of today, Maravai LifeSciences has 570 employees. |
| Who is the CEO of Maravai LifeSciences? | Maravai LifeSciences's CEO is Mr. William E. Martin, III. |
| Is Maravai LifeSciences publicy listed? | Yes, Maravai LifeSciences is a public company listed on NAS. |
| What is the stock symbol of Maravai LifeSciences? | Maravai LifeSciences trades under MRVI ticker. |
| When did Maravai LifeSciences go public? | Maravai LifeSciences went public in 2020. |
| Who are competitors of Maravai LifeSciences? | Similar companies to Maravai LifeSciences include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Maravai LifeSciences? | Maravai LifeSciences's current market cap is $254M |
| What is the current revenue of Maravai LifeSciences? | Maravai LifeSciences's last 12-month revenue is $240M. |
| What is the current EBITDA of Maravai LifeSciences? | Maravai LifeSciences's last 12-month EBITDA is $21.1M. |
| What is the current EV/Revenue multiple of Maravai LifeSciences? | Current revenue multiple of Maravai LifeSciences is 1.3x. |
| What is the current EV/EBITDA multiple of Maravai LifeSciences? | Current EBITDA multiple of Maravai LifeSciences is 14.6x. |
| What is the current revenue growth of Maravai LifeSciences? | Maravai LifeSciences revenue growth between 2023 and 2024 was -10%. |
| Is Maravai LifeSciences profitable? | Yes, Maravai LifeSciences is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
